
Astek Diagnostics LLC Profile last edited on: 8/9/2023
CAGE: 8QMK0
UEI: DWMKQ81LJLW1
Business Identifier: Platform (Eugris) guiding physician's prescription of appropriate antibiotics for patients. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: Baltimore
Congr. District: 03
County: Baltimore
Public Profile
A medical device company commercializing a novel technology for detecting bacterial infections in blood, Astek Diagnostics is addressing the problem of inappropriate use of antibiotics: too little or too much. The firm's website notes that the life-threatening Sepsis is a life-threatening condition annually involving more than 1 million US-based patients -- and even more worldwide -- making this one condition a leading causes of death. For those suspected of sepsis/septic shock, rapid initiation of correct antibiotic therapy is crucial: over 270,000 people die each year due to sepsis. Astek Diagnnostic's benchtop diagnostic device employs a single-use cartridge capable (in about one hour) of identification of bacterial infection in the blood antibiotic sensitivity. The firm's first product - EugrisTM, is a benchtop analyzer that - in that one hour - can identify presence of bacterial infection in blood and can perform antibiotic susceptibility testing (AST) of the bacterium. Result: in very short order, physicians are imformed which antibiotics would best be given to patients.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NSF | $274,587 | |
Project Title: Automated One-Hour Testing for Bacteremia and Antibiotic Sensitivity | ||||
2021 | 1 | NSF | $255,975 | |
Project Title: Rapid detection of blood-borne bacteria and determination of antibiotic resistance |
Key People / Management
Mustafa Al-Adhami -- CEO
Ashlee Brennan
Courtney Cavin
Rick Faint
Alastair Mackay
Ted Olsen
Kevin Tran -- CTO
Ashlee Brennan
Courtney Cavin
Rick Faint
Alastair Mackay
Ted Olsen
Kevin Tran -- CTO
Company News
There are no news available.